NRG Therapeutics

Therapeutics
Share

NRG Therapeutics, Ltd. is a neuroscience drug discovery company building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson’s and Amyotrophic Lateral Sclerosis (ALS), also known as motor neurone disease (MND). 

The company’s pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mPTP) through a novel mechanism of action. Inhibition of the mPTP has been shown to protect neurons, reduce neuroinflammation and extend survival in pre-clinical disease models.

See our new website showcasing our #innovative #science & pipeline of potential disease-modifying brain-penetrant oral first-in-class inhibitors of the mitochondrial permeability transition pore #mPTP for #NeurodegenerativeDisorders #ALS #MND #Parkinsons nrgtherapeutics.com

Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.

Learn more

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.